Francis Lo Sells 39,741 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 39,741 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $17.49, for a total transaction of $695,070.09. Following the transaction, the insider owned 250,934 shares in the company, valued at $4,388,835.66. The trade was a 13.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.07, for a total transaction of $340,039.48.
• On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.08, for a total transaction of $430,749.44.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock traded down $0.20 during trading hours on Monday, reaching $16.70. 1,749,340 shares of the company were exchanged, compared to its average volume of 1,691,541. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.90 and a fifty-two week high of $20.76. The stock’s fifty day moving average is $14.22 and its two-hundred day moving average is $15.65. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -50.61 and a beta of 2.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same period in the prior year, the business earned ($0.20) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis. On average, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on ADPT shares. Guggenheim restated a “buy” rating and issued a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Morgan Stanley cut their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average target price of $19.57.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC acquired a new stake in Adaptive Biotechnologies in the first quarter worth $2,117,000. Bank of America Corp DE raised its holdings in Adaptive Biotechnologies by 52.3% in the first quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock worth $17,043,000 after purchasing an additional 421,645 shares during the period. Amundi acquired a new stake in Adaptive Biotechnologies in the first quarter worth $148,000. California State Teachers Retirement System raised its holdings in Adaptive Biotechnologies by 28.4% in the first quarter. California State Teachers Retirement System now owns 143,658 shares of the company’s stock worth $1,994,000 after purchasing an additional 31,782 shares during the period. Finally, SummitTX Capital L.P. acquired a new stake in Adaptive Biotechnologies in the first quarter worth $4,409,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.